These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30926653)

  • 1. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
    Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice.
    Chen Y; Xiang X; Qi R; Wang Y; Huang Y; You M; Xian Y; Wu Y; Fu R; Kang C; Tang J; Yu H; Zhang T; Yuan Q; Luo W; Xia N
    Antib Ther; 2021 Oct; 4(4):197-207. PubMed ID: 34646979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
    Zhang TY; Yuan Q; Zhao JH; Zhang YL; Yuan LZ; Lan Y; Lo YC; Sun CP; Wu CR; Zhang JF; Zhang Y; Cao JL; Guo XR; Liu X; Mo XB; Luo WX; Cheng T; Chen YX; Tao MH; Shih JW; Zhao QJ; Zhang J; Chen PJ; Yuan YA; Xia NS
    Gut; 2016 Apr; 65(4):658-71. PubMed ID: 26423112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
    Zhou C; Peng G; Jin X; Tang J; Chen Z
    Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
    J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
    Tsuge M; Hiraga N; Uchida T; Kan H; Miyaki E; Masaki K; Ono A; Nakahara T; Abe-Chayama H; Zhang Y; Naswa MG; Kawaoka T; Miki D; Imamura M; Kawakami Y; Aikata H; Ochi H; Hayes CN; Chayama K
    J Gastroenterol; 2016 Nov; 51(11):1073-1080. PubMed ID: 26943168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
    Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
    Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.
    Morrey JD; Motter NE; Chang S; Fairman J
    Antiviral Res; 2011 Jun; 90(3):227-30. PubMed ID: 21545812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production.
    Chuai X; Xie B; Deng Y; Zhao Y; Wang W; Gao Z; Wang W; Qiu X; Tan W
    Antiviral Res; 2019 Jan; 161():20-27. PubMed ID: 30423362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Li X; Yang X; Li L; Liu H; Liu J
    Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model.
    Gotsman I; Beinart R; Alper R; Rabbani E; Engelhardt D; Ilan Y
    Antiviral Res; 2000 Oct; 48(1):17-26. PubMed ID: 11080537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice.
    Yoon SK; Seo YB; Im SJ; Bae SH; Song MJ; You CR; Jang JW; Yang SH; Suh YS; Song JS; Kim BM; Kim CY; Jeong SH; Sung YC
    Liver Int; 2015 Mar; 35(3):805-15. PubMed ID: 24620920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection.
    Dikici B; Bosnak M; Ucmak H; Dagli A; Ece A; Haspolat K
    J Gastroenterol Hepatol; 2003 Feb; 18(2):218-22. PubMed ID: 12542609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.